The digital biomarkers market size was valued at USD 4.77 billion in 2025 and is projected to grow from USD 5.68 billion in 2026 to USD 23.41 billion by 2034, registering a CAGR of 19.36% during the forecast period (2026–2034). North America dominated the digital biomarkers market with a market share of 47.60% in 2025.
Digital biomarkers are measurable physiological, behavioral, or biological data collected through digital technologies such as wearable devices, smartphones, sensors, and connected health platforms. These biomarkers help monitor disease progression, treatment response, patient behavior, and health outcomes.
The digital biomarkers market demand is driven by the adoption of remote patient monitoring, rising chronic disease prevalence, and connected healthcare technologies. Healthcare providers are adopting these solutions to improve outcomes and support informed decisions. Advances in artificial intelligence, wearable technology, and healthcare infrastructure are also contributing to digital biomarkers market growth.
Download a Free Sample To learn more about this report,
The digital biomarkers market is sensitive to disruptions because its ecosystem relies on globally sourced wearable devices, sensors, semiconductors, connected hardware, and specialized components. Supply interruptions, manufacturing constraints, logistics delays, and geopolitical events can increase component costs, extend product delivery timelines, and affect the deployment of digital biomarker solutions across clinical research and healthcare settings. The market is demonstrating an elastic recovery pattern, as manufacturers and technology providers gradually restore component availability through supplier diversification, capacity adjustments, inventory optimization, and contingency planning, enabling digital biomarker deployment to recover as supply conditions stabilize.
Expansion of Passive Voice Biomarkers for Neurological Disease Monitoring
Smartphone-based voice capture is increasingly being used to develop passive digital biomarkers for neurological disease monitoring. Rather than relying only on scheduled clinical assessments, these technologies analyze speech characteristics collected during routine smartphone interactions, enabling more continuous and convenient tracking of disease-related changes.
Shift Toward Multimodal Wearable Biomarkers in Clinical Trials
Wearable technologies are increasingly being integrated into clinical trials to capture multiple physiological and behavioral measures rather than relying on single biomarkers. Instead of collecting isolated data points, connected devices can simultaneously monitor parameters such as sleep, cardiovascular function, physical activity, and movement, enabling broader assessment of patient health in real-world settings.
The digital biomarkers market forecasts continued investment activity as pharmaceutical companies, healthcare providers, and technology firms increase spending on remote monitoring, AI-enabled biomarker platforms, wearable technologies, and digital endpoints for clinical trials. In November 2025, Indivi secured USD 18 million in investment to accelerate the discovery of treatment-response biomarkers for neuroscience drug development, with a specific focus on Alzheimer’s disease. The funding will support the advancement of Indivi’s digital biomarker platform, enabling researchers to identify and measure treatment responses using objective, data-driven assessments.
Adoption of Remote Patient Monitoring and Demand for Objective Clinical Endpoints Drive Market
The growing adoption of remote patient monitoring is driving demand for digital biomarkers by enabling healthcare providers and clinical researchers to continuously collect objective physiological and behavioral data outside traditional clinical settings. Wearable devices, smartphones, and connected sensors can capture measures such as activity, sleep, heart rate, speech, and movement, supporting more frequent assessment of patient health. The US FDA continues to support the use of digital health technologies for remote data collection in drug development, accelerating adoption of digital biomarkers and contributing to market growth.
The increasing demand for objective and measurable clinical endpoints is creating opportunities for advanced digital biomarker technologies across clinical trials and disease management. Digital biomarkers can provide longitudinal insights into disease progression, treatment response, and patient behavior, particularly in neurological, cardiovascular, and chronic diseases.
High Costs of Wearable Devices and Data Privacy Requirements Restrain Market Expansion
Digital biomarker implementation often requires wearable devices, smartphones, sensors, software platforms, data storage, and specialized analytics infrastructure, creating significant upfront and recurring costs for healthcare providers and clinical research organizations. These expenses can limit adoption among smaller healthcare facilities and organizations with constrained technology budgets, particularly in emerging markets.
Digital biomarkers rely on continuous collection of sensitive physiological, behavioral, and health-related information, increasing concerns regarding data privacy, cybersecurity, consent, and regulatory compliance. Requirements such as HIPAA in the US and GDPR in Europe can create additional operational and technical requirements for organizations collecting and processing digital biomarker data.
Integration of Digital Biomarkers into Decentralized Clinical Trials and Expansion of Precision Medicine Offer Growth Opportunities to Market Players
The expansion of decentralized and hybrid clinical trials presents a significant market opportunity for digital biomarker providers. Wearables, smartphones, connected sensors, and remote monitoring platforms enable continuous collection of physiological and behavioral data outside conventional clinical settings, reducing dependence on frequent site visits. For example, Roche’s Floodlight MS app uses smartphone-based digital measures to assess cognitive and motor functions in people with multiple sclerosis, demonstrating how digital biomarkers can support continuous disease monitoring and create opportunities for remote, patient-centered clinical assessment.
The expansion of precision medicine presents a significant opportunity for digital biomarker providers by enabling more personalized disease assessment, patient stratification, and treatment monitoring. Digital biomarkers can combine physiological, behavioral, and clinical data collected through wearables, smartphones, and connected sensors to identify individual disease patterns and differences in treatment response. As healthcare moves toward individualized care, demand for validated digital biomarkers that provide continuous and patient-specific insights is expected to increase.
Need to Ensure Clinical Validation and Manage Data Standardization Hinder Growth
Digital biomarkers can vary based on sensor type, measurement conditions, software algorithms, patient behavior, and data collection protocols. Healthcare providers and pharmaceutical companies therefore require robust evidence demonstrating accuracy, reliability, reproducibility, and clinical relevance before integrating these technologies into routine care or clinical trials.
Variations in device specifications, data formats, sampling frequencies, and analytical methods can affect biomarker reliability. Organizations therefore require standardized data protocols, robust analytical frameworks, and quality control processes, increasing technical complexity and operational requirements across the digital biomarker ecosystem.
The wearable segment accounted for a share of 40.05% in 2025 due to continuous physiological sensing and established health tracking ecosystems. The integration of multi-sensor measurements and improved battery performance strengthens their suitability for long-duration digital biomarker collection.
The mobile applications segment is expected to grow at a CAGR of 20.24% during the forecast period, driven by smartphone ubiquity, software-based assessments, and low hardware requirements. The integration of passive data collection, smartphone sensors, and remote patient interfaces further supports segment growth.
Request Customizationto receive a tailored report.
In 2025, diagnostic digital biomarkers accounted for a share of 49.33%, supported by objective disease identification, algorithm-based screening, and growing clinical validation. Their ability to detect subtle physiological and behavioral changes strengthens diagnostic applications.
The monitoring digital biomarkers segment is expected to grow at a CAGR of 20.56% during the forecast period, fueled by continuous disease tracking and longitudinal patient monitoring. Integration with connected devices enables frequent assessment of disease progression, supporting personalized care pathways and reducing dependence on intermittent clinical evaluations.
The cardiovascular & metabolic disorders segment accounted for a share of 40.18% in 2025 due to physiological parameters, high chronic disease prevalence, and established wearable monitoring applications. Continuous tracking of heart rate, glucose-related measures, activity, and sleep supports earlier identification of clinically relevant changes.
The neurological disorders segment is expected to grow at a CAGR of 20.82% during the forecast period, propelled by digital assessment of cognition, gait, speech, and movement. Smartphone and wearable data support longitudinal neurological monitoring.
The pharmaceutical & biotechnology companies accounted for a share of 38.79% in 2025, driven by digital endpoint development and decentralized clinical trials. Digital biomarkers enable continuous treatment-response measurement and improve data collection across drug development programs.
The payers & employers segment is projected to grow at a CAGR of 20.17% during the forecast period, driven by risk stratification and employee wellness programs. Digital biomarkers support early identification of high-risk populations and enable targeted preventive interventions, improving population health management.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Advanced Digital Health Infrastructure and Strong Clinical Trial Adoption
The North America digital biomarkers market accounted for the largest regional share of 47.60% in 2025, driven by adoption of wearable technologies, advanced digital health infrastructure, strong pharmaceutical R&D activity, and increasing use of remote patient monitoring.
The US digital biomarkers market was valued at USD 1.96 billion in 2025, driven by increasing adoption of decentralized clinical trials and growing demand for objective digital endpoints. Healthcare providers and research organizations are increasingly using smartphones, wearables, and connected sensors to collect continuous physiological and behavioral data.
The digital biomarkers market in Canada was valued at USD 308.53 million in 2025, supported by growing digital health adoption, expanding clinical research capabilities, and increasing use of remote monitoring technologies. Healthcare organizations and researchers are adopting wearable devices, smartphone applications, and connected technologies to improve longitudinal patient monitoring and generate real-world health data.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Driven by Mobile Health Adoption and Expansion of Digital-First Healthcare Models
The Asia Pacific digital biomarkers market is expected to grow at a CAGR of 21.17% during the forecast period, showcasing the fastest regional growth. Growth is supported by smartphone penetration, expanding telehealth services, increasing digital health investments, and growing use of connected devices.
The China digital biomarkers market was valued at USD 278.70 million in 2025, supported by expanding domestic wearable device ecosystems and increasing integration of digital technologies into clinical services. The country’s expanding digital healthcare infrastructure and increasing investment in artificial intelligence are creating opportunities for digital biomarkers across chronic disease monitoring, neurological assessment, and personalized healthcare.
The India digital biomarkers market was valued at USD 140.79 million in 2025, fueled by ABDM-driven health-data interoperability, growing adoption of ABHA-linked health records, and increasing integration of healthcare providers with national digital infrastructure. The country’s expanding digital health framework is creating a stronger foundation for longitudinal patient data collection and biomarker development.
The Japan digital biomarkers market was valued at USD 165.02 million in 2025, supported by government-backed digital health commercialization programs, evidence-based validation of wearable and IoT health technologies, and strong demand for healthy aging solutions. Japan’s AMED is funding projects that validate wearable-based interventions and digital technologies for frailty, cognitive health, and chronic disease prevention.
The digital biomarkers market competitive landscape is moderately fragmented, with competition spanning established healthcare technology companies, pharmaceutical firms, wearable manufacturers, and specialized digital health providers. Leading players compete through advanced sensor technologies, AI-driven analytics, clinical validation, data security, and integration with healthcare and clinical trial platforms. Emerging players focus on developing disease-specific biomarkers, remote monitoring capabilities, and personalized digital endpoints.
July 8, 2026: The Global Alzheimer’s Platform Foundation announced a strategic partnership with Taudia for the Bio-Hermes-002 study, expanding research that evaluates digital and blood-based biomarkers alongside MRI and PET imaging.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Sleep Apnea Devices Market Size, Share, Growth, Analysis, 2034
Smart Insulin Pens Market Size, Share, Growth, Analysis, 2034
Temperature Management Market Size, Share, Growth, Analysis, 2034
Vessel Sealing Devices Market Size, Share, Growth, Analysis, 2034
ECG Patch and Holter Monitor Market Size, Share, Growth, 2034
Cannula Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com